Molecular Diagnostics Market by Offering (Instruments, Reagents & Kits, Software & Services), Technology (Fluorescence In Situ Hybridization, Mass Spectrometry, Microarray Analysis), Specimen Type, Test Type, Application, End User - Global Forecast 2025-2
Description
The Molecular Diagnostics Market was valued at USD 28.02 billion in 2024 and is projected to grow to USD 31.86 billion in 2025, with a CAGR of 14.29%, reaching USD 81.60 billion by 2032.
Establishing the Strategic Importance of Molecular Diagnostics as a Cornerstone for Personalized Medicine and Advanced Healthcare Decision-Making
Molecular diagnostics has rapidly emerged as a foundational pillar in the pursuit of more precise and personalized healthcare. By directly interrogating genetic material, proteins, and other biomarkers, these technologies enable clinicians to diagnose conditions with unprecedented accuracy, guide targeted therapies, and monitor treatment efficacy. Consequently, molecular assays are reshaping disease management paradigms across oncology, infectious diseases, prenatal screening, and genetic disorders. This executive summary distills the pivotal factors influencing market evolution, from technological breakthroughs and shifting regulatory frameworks to global supply chain dynamics and competitive landscapes.
Drawing upon a rigorous synthesis of primary interviews with industry experts and secondary research from peer-reviewed publications, regulatory filings, and corporate disclosures, this document offers a strategic vantage point for senior decision-makers. Within these pages, you will discover how emerging methods such as digital PCR and RNA sequencing are displacing legacy platforms, the implications of newly imposed tariffs on imports, and actionable insights derived from nuanced segmentation spanning offering, technology, specimen, test, application, and end user. Through a balanced lens of data integrity and forward-looking analysis, this introduction sets the stage for a comprehensive exploration of the molecular diagnostics ecosystem.
Mapping the Pivotal Technological and Market Dynamics Driving Revolutionary Shifts in Diagnostics Delivery Across the Molecular Testing Landscape
The molecular diagnostics landscape is undergoing revolutionary transformation driven by converging technological, regulatory, and market forces. Innovations in high-throughput sequencing platforms are now complemented by miniaturized point-of-care devices, enabling faster turnaround times and decentralizing the testing paradigm. Meanwhile, the integration of advanced bioinformatics pipelines and artificial intelligence has elevated data analytics from descriptive reporting to predictive and prescriptive insights. As a result, laboratories are investing in seamless connectivity between instruments, laboratory information systems, and electronic health records to accelerate workflows and enhance decision support.
Furthermore, regulatory bodies worldwide are revising approval pathways to accommodate novel diagnostics, creating expedited routes for breakthrough devices while enforcing rigorous quality standards. These evolving frameworks are fostering collaborations between diagnostic firms and pharmaceutical companies to co-develop companion diagnostics that align with targeted therapies. In addition, heightened awareness of antimicrobial resistance and the need for rapid pathogen identification is spurring demand for multiplex assays capable of detecting multiple agents in a single run. Consequently, the cumulative effect of these shifts is forging a molecular diagnostics ecosystem that is more adaptive, data-centric, and patient-focused than ever before.
Evaluating the Comprehensive Consequences of Newly Imposed United States Tariffs on Molecular Diagnostics Components and Supply Chains in 2025
The imposition of new tariffs by the United States in 2025 has exerted measurable pressure on the molecular diagnostics supply chain. Instruments and critical reagents imported from key manufacturing hubs now carry elevated duties, driving up acquisition costs for laboratories and research centers. Consequently, procurement teams are reassessing vendor agreements and negotiating long-term contracts to mitigate price volatility. At the same time, some domestic manufacturers are scaling up production to capture market share, although capacity constraints remain a concern in the near term.
Moreover, the cost impact extends beyond hardware and consumables. Software licensing fees, technical support services, and calibration contracts have also seen incremental increases as service providers adjust pricing structures to offset tariff-induced expenses. To navigate this complex landscape, industry stakeholders are exploring alternative sourcing strategies, including regional partnerships and in-country assembly. Additionally, collaborative procurement consortia are emerging to leverage collective bargaining power and optimize inventory management. Moving forward, the ability to adapt supply chain configurations and establish resilient logistics networks will prove essential in preserving operational continuity and sustaining growth under the new tariff regime.
Unveiling Actionable Insights from Multifaceted Market Segmentation to Drive Strategic Investments and Product Development in Molecular Diagnostics
A comprehensive examination of market segmentation reveals distinct trajectories and investment priorities across the molecular diagnostics value chain. Based on offering, the industry encompasses instruments, reagents and kits, and software and services, each representing critical nodes in the testing workflow. Within technology streams, established methods such as fluorescence in situ hybridization and mass spectrometry coexist with emerging high-throughput approaches including microarray analysis and next-generation sequencing, the latter subdivided into exome, RNA, targeted, and whole genome applications. Parallel to this, polymerase chain reaction techniques have evolved to support digital, multiplex, and real-time formats.
Specimen diversity underscores the versatility of molecular diagnostics, with blood, cerebrospinal fluid, nasal and throat swabs, saliva, stool, tissue biopsies, and urine serving as analytes for a broad spectrum of disease states. Testing modalities bifurcate into laboratory-based workflows conducted in central labs, hospital labs, and independent labs, as well as point-of-care solutions deployed at the patient’s side. Application domains range from genetic testing-spanning carrier, diagnostic, and predictive assessments-to infectious disease panels targeting bacterial, parasitic, and viral pathogens, oncology assays including liquid biopsy, minimal residual disease, and tissue biopsy, and prenatal screenings available through invasive and non-invasive approaches. Lastly, end user categories such as academic and research institutes, diagnostic laboratories, and hospitals and clinics drive tailored service models and purchasing behaviors.
Deriving Critical Regional Perspectives on Molecular Diagnostics Adoption and Innovation Momentum Across Key Global Markets
Regional dynamics are reshaping the pace and direction of molecular diagnostics adoption across global markets. In the Americas, robust research infrastructure and high healthcare expenditure underpin accelerated uptake of next-generation sequencing platforms, digital PCR, and integrated informatics solutions. Regulatory agencies in North America have implemented streamlined approval processes, enabling faster market entry for innovative assays and companion diagnostics. Meanwhile, Latin American markets are demonstrating growing demand for cost-effective infectious disease testing as public health initiatives expand testing coverage.
Across Europe, Middle East and Africa, collaborative research consortia and government funding programs are fueling projects in genomic medicine and molecular pathology. Harmonization of regulatory standards across the European Union is enhancing cross-border trade while national authorities in the Middle East invest in local manufacturing capabilities to reduce import dependency. In Africa, public-private partnerships are enabling roll-out of molecular platforms to combat endemic diseases. In the Asia-Pacific region, rising healthcare budgets and escalating incidence of chronic and infectious diseases are driving procurement of advanced diagnostics. Key manufacturing and research hubs in countries such as China, Japan, and India are further strengthening regional supply chains and export potential.
Identifying Leading Innovators and Strategic Collaborations Shaping Tomorrow’s Frontiers in Molecular Diagnostics Research and Commercialization
Leading corporations are differentiating their molecular diagnostics portfolios through strategic collaborations, targeted acquisitions, and continuous innovation. Companies specializing in high-throughput sequencing have expanded service offerings by integrating bioinformatics capabilities and cloud-based analytics, while traditional instrument manufacturers have formed alliances with software developers to deliver end-to-end solutions. In parallel, reagent suppliers are introducing ready-to-use kits optimized for both established and emerging platforms, enhancing reproducibility and reducing hands-on time.
Moreover, several market participants have forged partnerships with academic institutions and healthcare networks to co-develop companion diagnostics for novel therapeutics. Investments in decentralized testing formats and multiplex assay panels reflect a commitment to drive faster diagnostics in near-patient settings. In addition, a cohort of agile biotech firms is gaining traction by focusing on niche applications such as liquid biopsy and microbial genomics. Collectively, these concerted efforts underscore a competitive landscape defined by cross-sector collaboration, technology convergence, and relentless pursuit of improved clinical outcomes.
Recommending Targeted Strategic Imperatives to Optimize Supply Chains, Accelerate Innovation, and Enhance Patient Outcomes in Molecular Diagnostics
Industry leaders must adopt a multifaceted approach to maintain competitive advantage and foster sustainable growth. First, diversifying supply chains to incorporate regional manufacturing and alternative sourcing will mitigate exposure to tariff fluctuations and logistical disruptions. Second, accelerating investment in automation and digital integration can streamline workflows, reduce labor costs, and enhance data interoperability across diagnostic networks. Third, forging strategic alliances with software and bioinformatics providers will enable rapid deployment of advanced analytics and artificial intelligence tools that unlock deeper insights from complex genomic datasets.
Furthermore, organizations should prioritize development of point-of-care assays to meet the growing demand for decentralized testing, particularly in outpatient and remote clinical settings. Engaging with regulatory authorities early in the development cycle can facilitate expedited approvals and ensure compliance with evolving quality standards. Finally, reinforcing partnerships with healthcare providers and payers will help align value-based care models with diagnostic offerings, driving adoption and reimbursement. By executing these targeted imperatives, industry stakeholders can enhance resilience, accelerate innovation, and ultimately improve patient outcomes in the molecular diagnostics arena.
Detailing a Rigorous Multi-Source Research Methodology Underpinning Insights, Ensuring Data Integrity and Analytical Precision in Molecular Diagnostics Market Assessment
This analysis is underpinned by a robust multi-source research methodology designed to ensure the highest degree of data integrity and analytical precision. Secondary research formed the foundation of our approach, encompassing peer-reviewed journals, industry white papers, regulatory filings, and proprietary databases. These insights were supplemented by primary interviews with senior executives, laboratory directors, academic thought leaders, and key opinion leaders across geographies and functional domains.
Data triangulation was rigorously applied to validate findings, cross-referencing market intelligence with financial filings, press releases, and patent databases. Quantitative assessments were enriched through in-depth case studies and real-world evidence from clinical laboratories, while qualitative insights were captured via structured discussions with end users to gauge adoption drivers and unmet needs. Continuous peer review and iterative validation cycles ensured that hypotheses were tested against multiple data points, delivering a comprehensive, balanced perspective on the molecular diagnostics ecosystem.
Synthesizing Strategic Takeaways to Empower Stakeholders with a Cohesive Roadmap for Navigating the Evolving Molecular Diagnostics Ecosystem
As molecular diagnostics continues its trajectory from research laboratories to mainstream clinical practice, stakeholders must remain agile and informed. The convergence of high-throughput sequencing, advanced PCR methodologies, and integrated data analytics is redefining disease detection and monitoring. At the same time, market access strategies must adapt to shifting regulatory landscapes and geopolitical factors that influence supply chain stability.
By synthesizing segmented insights, regional dynamics, and competitive intelligence, this report equips decision-makers with a cohesive roadmap to prioritize investments, streamline operations, and cultivate strategic partnerships. Looking ahead, the ability to harness technological innovations, navigate policy changes, and align diagnostic solutions with evolving healthcare models will determine market leadership. Ultimately, those organizations that blend scientific excellence with operational resilience and customer-centricity will thrive in the rapidly evolving molecular diagnostics ecosystem.
Please Note: PDF & Excel + Online Access - 1 Year
Establishing the Strategic Importance of Molecular Diagnostics as a Cornerstone for Personalized Medicine and Advanced Healthcare Decision-Making
Molecular diagnostics has rapidly emerged as a foundational pillar in the pursuit of more precise and personalized healthcare. By directly interrogating genetic material, proteins, and other biomarkers, these technologies enable clinicians to diagnose conditions with unprecedented accuracy, guide targeted therapies, and monitor treatment efficacy. Consequently, molecular assays are reshaping disease management paradigms across oncology, infectious diseases, prenatal screening, and genetic disorders. This executive summary distills the pivotal factors influencing market evolution, from technological breakthroughs and shifting regulatory frameworks to global supply chain dynamics and competitive landscapes.
Drawing upon a rigorous synthesis of primary interviews with industry experts and secondary research from peer-reviewed publications, regulatory filings, and corporate disclosures, this document offers a strategic vantage point for senior decision-makers. Within these pages, you will discover how emerging methods such as digital PCR and RNA sequencing are displacing legacy platforms, the implications of newly imposed tariffs on imports, and actionable insights derived from nuanced segmentation spanning offering, technology, specimen, test, application, and end user. Through a balanced lens of data integrity and forward-looking analysis, this introduction sets the stage for a comprehensive exploration of the molecular diagnostics ecosystem.
Mapping the Pivotal Technological and Market Dynamics Driving Revolutionary Shifts in Diagnostics Delivery Across the Molecular Testing Landscape
The molecular diagnostics landscape is undergoing revolutionary transformation driven by converging technological, regulatory, and market forces. Innovations in high-throughput sequencing platforms are now complemented by miniaturized point-of-care devices, enabling faster turnaround times and decentralizing the testing paradigm. Meanwhile, the integration of advanced bioinformatics pipelines and artificial intelligence has elevated data analytics from descriptive reporting to predictive and prescriptive insights. As a result, laboratories are investing in seamless connectivity between instruments, laboratory information systems, and electronic health records to accelerate workflows and enhance decision support.
Furthermore, regulatory bodies worldwide are revising approval pathways to accommodate novel diagnostics, creating expedited routes for breakthrough devices while enforcing rigorous quality standards. These evolving frameworks are fostering collaborations between diagnostic firms and pharmaceutical companies to co-develop companion diagnostics that align with targeted therapies. In addition, heightened awareness of antimicrobial resistance and the need for rapid pathogen identification is spurring demand for multiplex assays capable of detecting multiple agents in a single run. Consequently, the cumulative effect of these shifts is forging a molecular diagnostics ecosystem that is more adaptive, data-centric, and patient-focused than ever before.
Evaluating the Comprehensive Consequences of Newly Imposed United States Tariffs on Molecular Diagnostics Components and Supply Chains in 2025
The imposition of new tariffs by the United States in 2025 has exerted measurable pressure on the molecular diagnostics supply chain. Instruments and critical reagents imported from key manufacturing hubs now carry elevated duties, driving up acquisition costs for laboratories and research centers. Consequently, procurement teams are reassessing vendor agreements and negotiating long-term contracts to mitigate price volatility. At the same time, some domestic manufacturers are scaling up production to capture market share, although capacity constraints remain a concern in the near term.
Moreover, the cost impact extends beyond hardware and consumables. Software licensing fees, technical support services, and calibration contracts have also seen incremental increases as service providers adjust pricing structures to offset tariff-induced expenses. To navigate this complex landscape, industry stakeholders are exploring alternative sourcing strategies, including regional partnerships and in-country assembly. Additionally, collaborative procurement consortia are emerging to leverage collective bargaining power and optimize inventory management. Moving forward, the ability to adapt supply chain configurations and establish resilient logistics networks will prove essential in preserving operational continuity and sustaining growth under the new tariff regime.
Unveiling Actionable Insights from Multifaceted Market Segmentation to Drive Strategic Investments and Product Development in Molecular Diagnostics
A comprehensive examination of market segmentation reveals distinct trajectories and investment priorities across the molecular diagnostics value chain. Based on offering, the industry encompasses instruments, reagents and kits, and software and services, each representing critical nodes in the testing workflow. Within technology streams, established methods such as fluorescence in situ hybridization and mass spectrometry coexist with emerging high-throughput approaches including microarray analysis and next-generation sequencing, the latter subdivided into exome, RNA, targeted, and whole genome applications. Parallel to this, polymerase chain reaction techniques have evolved to support digital, multiplex, and real-time formats.
Specimen diversity underscores the versatility of molecular diagnostics, with blood, cerebrospinal fluid, nasal and throat swabs, saliva, stool, tissue biopsies, and urine serving as analytes for a broad spectrum of disease states. Testing modalities bifurcate into laboratory-based workflows conducted in central labs, hospital labs, and independent labs, as well as point-of-care solutions deployed at the patient’s side. Application domains range from genetic testing-spanning carrier, diagnostic, and predictive assessments-to infectious disease panels targeting bacterial, parasitic, and viral pathogens, oncology assays including liquid biopsy, minimal residual disease, and tissue biopsy, and prenatal screenings available through invasive and non-invasive approaches. Lastly, end user categories such as academic and research institutes, diagnostic laboratories, and hospitals and clinics drive tailored service models and purchasing behaviors.
Deriving Critical Regional Perspectives on Molecular Diagnostics Adoption and Innovation Momentum Across Key Global Markets
Regional dynamics are reshaping the pace and direction of molecular diagnostics adoption across global markets. In the Americas, robust research infrastructure and high healthcare expenditure underpin accelerated uptake of next-generation sequencing platforms, digital PCR, and integrated informatics solutions. Regulatory agencies in North America have implemented streamlined approval processes, enabling faster market entry for innovative assays and companion diagnostics. Meanwhile, Latin American markets are demonstrating growing demand for cost-effective infectious disease testing as public health initiatives expand testing coverage.
Across Europe, Middle East and Africa, collaborative research consortia and government funding programs are fueling projects in genomic medicine and molecular pathology. Harmonization of regulatory standards across the European Union is enhancing cross-border trade while national authorities in the Middle East invest in local manufacturing capabilities to reduce import dependency. In Africa, public-private partnerships are enabling roll-out of molecular platforms to combat endemic diseases. In the Asia-Pacific region, rising healthcare budgets and escalating incidence of chronic and infectious diseases are driving procurement of advanced diagnostics. Key manufacturing and research hubs in countries such as China, Japan, and India are further strengthening regional supply chains and export potential.
Identifying Leading Innovators and Strategic Collaborations Shaping Tomorrow’s Frontiers in Molecular Diagnostics Research and Commercialization
Leading corporations are differentiating their molecular diagnostics portfolios through strategic collaborations, targeted acquisitions, and continuous innovation. Companies specializing in high-throughput sequencing have expanded service offerings by integrating bioinformatics capabilities and cloud-based analytics, while traditional instrument manufacturers have formed alliances with software developers to deliver end-to-end solutions. In parallel, reagent suppliers are introducing ready-to-use kits optimized for both established and emerging platforms, enhancing reproducibility and reducing hands-on time.
Moreover, several market participants have forged partnerships with academic institutions and healthcare networks to co-develop companion diagnostics for novel therapeutics. Investments in decentralized testing formats and multiplex assay panels reflect a commitment to drive faster diagnostics in near-patient settings. In addition, a cohort of agile biotech firms is gaining traction by focusing on niche applications such as liquid biopsy and microbial genomics. Collectively, these concerted efforts underscore a competitive landscape defined by cross-sector collaboration, technology convergence, and relentless pursuit of improved clinical outcomes.
Recommending Targeted Strategic Imperatives to Optimize Supply Chains, Accelerate Innovation, and Enhance Patient Outcomes in Molecular Diagnostics
Industry leaders must adopt a multifaceted approach to maintain competitive advantage and foster sustainable growth. First, diversifying supply chains to incorporate regional manufacturing and alternative sourcing will mitigate exposure to tariff fluctuations and logistical disruptions. Second, accelerating investment in automation and digital integration can streamline workflows, reduce labor costs, and enhance data interoperability across diagnostic networks. Third, forging strategic alliances with software and bioinformatics providers will enable rapid deployment of advanced analytics and artificial intelligence tools that unlock deeper insights from complex genomic datasets.
Furthermore, organizations should prioritize development of point-of-care assays to meet the growing demand for decentralized testing, particularly in outpatient and remote clinical settings. Engaging with regulatory authorities early in the development cycle can facilitate expedited approvals and ensure compliance with evolving quality standards. Finally, reinforcing partnerships with healthcare providers and payers will help align value-based care models with diagnostic offerings, driving adoption and reimbursement. By executing these targeted imperatives, industry stakeholders can enhance resilience, accelerate innovation, and ultimately improve patient outcomes in the molecular diagnostics arena.
Detailing a Rigorous Multi-Source Research Methodology Underpinning Insights, Ensuring Data Integrity and Analytical Precision in Molecular Diagnostics Market Assessment
This analysis is underpinned by a robust multi-source research methodology designed to ensure the highest degree of data integrity and analytical precision. Secondary research formed the foundation of our approach, encompassing peer-reviewed journals, industry white papers, regulatory filings, and proprietary databases. These insights were supplemented by primary interviews with senior executives, laboratory directors, academic thought leaders, and key opinion leaders across geographies and functional domains.
Data triangulation was rigorously applied to validate findings, cross-referencing market intelligence with financial filings, press releases, and patent databases. Quantitative assessments were enriched through in-depth case studies and real-world evidence from clinical laboratories, while qualitative insights were captured via structured discussions with end users to gauge adoption drivers and unmet needs. Continuous peer review and iterative validation cycles ensured that hypotheses were tested against multiple data points, delivering a comprehensive, balanced perspective on the molecular diagnostics ecosystem.
Synthesizing Strategic Takeaways to Empower Stakeholders with a Cohesive Roadmap for Navigating the Evolving Molecular Diagnostics Ecosystem
As molecular diagnostics continues its trajectory from research laboratories to mainstream clinical practice, stakeholders must remain agile and informed. The convergence of high-throughput sequencing, advanced PCR methodologies, and integrated data analytics is redefining disease detection and monitoring. At the same time, market access strategies must adapt to shifting regulatory landscapes and geopolitical factors that influence supply chain stability.
By synthesizing segmented insights, regional dynamics, and competitive intelligence, this report equips decision-makers with a cohesive roadmap to prioritize investments, streamline operations, and cultivate strategic partnerships. Looking ahead, the ability to harness technological innovations, navigate policy changes, and align diagnostic solutions with evolving healthcare models will determine market leadership. Ultimately, those organizations that blend scientific excellence with operational resilience and customer-centricity will thrive in the rapidly evolving molecular diagnostics ecosystem.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
193 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of AI-driven analysis platforms to transform high-throughput molecular diagnostics workflows
- 5.2. Adoption of decentralized next-generation sequencing panels empowering precision medicine in remote healthcare settings
- 5.3. Emergence of multiplexed liquid biopsy assays enabling noninvasive cancer screening and monitoring capabilities
- 5.4. Increasing regulatory approvals for companion diagnostics fueling personalized oncology treatment selection globally
- 5.5. Expanding use of CRISPR-based point-of-care diagnostic assays facilitating rapid pathogen detection
- 5.6. Advancements in microfluidic lab-on-a-chip platforms to reduce assay volumes and turnaround times for molecular testing
- 5.7. Rising implementation of digital PCR technologies to enhance sensitivity and quantification accuracy in rare mutation detection
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Molecular Diagnostics Market, by Offering
- 8.1. Instruments
- 8.2. Reagents & Kits
- 8.3. Software & Services
- 9. Molecular Diagnostics Market, by Technology
- 9.1. Fluorescence In Situ Hybridization
- 9.2. Mass Spectrometry
- 9.3. Microarray Analysis
- 9.4. Next-Generation Sequencing
- 9.4.1. Exome Sequencing
- 9.4.2. RNA Sequencing
- 9.4.3. Targeted Sequencing
- 9.4.4. Whole Genome Sequencing
- 9.5. Polymerase Chain Reaction
- 9.5.1. Digital PCR
- 9.5.2. Multiplex PCR
- 9.5.3. Real-Time PCR
- 10. Molecular Diagnostics Market, by Specimen Type
- 10.1. Blood
- 10.2. Cerebrospinal Fluid (CSF)
- 10.3. Nasal/Throat Swabs
- 10.4. Saliva
- 10.5. Stool
- 10.6. Tissue Biopsies
- 10.7. Urine
- 11. Molecular Diagnostics Market, by Test Type
- 11.1. Laboratory Based
- 11.1.1. Central Lab
- 11.1.2. Hospital Lab
- 11.1.3. Independent Lab
- 11.2. Point Of Care
- 12. Molecular Diagnostics Market, by Application
- 12.1. Genetic Testing
- 12.1.1. Carrier Testing
- 12.1.2. Diagnostic Testing
- 12.1.3. Predictive Testing
- 12.2. Infectious Disease
- 12.2.1. Bacterial
- 12.2.2. Parasitic
- 12.2.3. Viral
- 12.3. Oncology
- 12.3.1. Liquid Biopsy
- 12.3.2. Minimal Residual Disease
- 12.3.3. Tissue Biopsy
- 12.4. Prenatal Testing
- 12.4.1. Invasive
- 12.4.2. Non-Invasive
- 13. Molecular Diagnostics Market, by End User
- 13.1. Academic & Research Institutes
- 13.2. Diagnostic Laboratories
- 13.3. Hospitals & Clinics
- 14. Molecular Diagnostics Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Molecular Diagnostics Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Molecular Diagnostics Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Abbott Laboratories Inc.
- 17.3.2. ADT Biotech Co., Ltd.
- 17.3.3. AstraZeneca plc
- 17.3.4. Becton, Dickinson, and Company
- 17.3.5. Bio-Rad Laboratories, Inc.
- 17.3.6. Biocartis Group NV
- 17.3.7. bioMérieux SA
- 17.3.8. Castle Biosciences, Inc.
- 17.3.9. Danaher Corporation
- 17.3.10. Diasorin S.p,A.
- 17.3.11. Exact Sciences Corporation
- 17.3.12. F. Hoffmann-La Roche AG
- 17.3.13. Grifols S.A.
- 17.3.14. Guardant Health, Inc.
- 17.3.15. Hologic, Inc.
- 17.3.16. Illumina, Inc.
- 17.3.17. Laboratory Corporation of America Holdings
- 17.3.18. Myriad Genetics, Inc.
- 17.3.19. Oxford Nanopore Technologies
- 17.3.20. QIAGEN N.V.
- 17.3.21. Siemens Healthineers AG
- 17.3.22. Source BioScience
- 17.3.23. Sysmex Corporation by Oxford Gene Technology
- 17.3.24. Thermo Fisher Scientific Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
